Drug Trial Radar · NCT05406440
A Study of Elpipodect (MK-8189) in Participants With Schizophrenia (MK-8189-014)
Last checked: Nov 20, 2026Latest source record: Apr 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
53
Actual
Start
Jul 12, 2022
Primary completion
Feb 24, 2023
Study completion Feb 24, 2023
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Jun 6, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to assess the safety and tolerability of multiple ascending doses of elpipodect in participants with schizophrenia.
Conditions
- Schizophrenia
Interventions
ElpipodectDrug
MK-8189 4 mg and/or 12 mg tablet(s) will be administered orally QD for a total daily dose of 48 mg, 60 mg, 80 mg.
PlaceboDrug
MK-8189 dose-matching placebo tablets will be administered orally QD.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Experiencing an Adverse Event (AE)Time frame: Up to approximately 17 days
- Number of Participants Who Discontinue From Study Treatment Due to an AETime frame: Up to approximately 3 days
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Collaborative Neuroscience Research, LLC ( Site 0004)
Garden Grove, California
California Clinical Trials Medical Group managed by PAREXEL ( Site 0002)
Glendale, California
Hassman Research Institute Marlton Site ( Site 0003)
Marlton, New Jersey
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.